Efficacy of xanomeline and xanomeline trospium in the treatment of cognitive impairment: A systematic review of preclinical and clinical trials

This publication has 68 references indexed in Scilit:

• Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia
  JAMA Psychiatry, 2024
• Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
  Psychopharmacology, 2023
• Recent Advances in Cholinergic Imaging and Cognitive Decline—Revisiting the Cholinergic Hypothesis of Dementia
  Current Geriatrics Reports, 2018
• Effects of NMDA receptor antagonists and antipsychotics on high frequency oscillations recorded in the nucleus accumbens of freely moving mice
  Psychopharmacology, 2015
• The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder
  CNS Drugs, 2015
• Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey
  Psychopharmacology, 2014
• Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats
  Psychopharmacology, 2013
• COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS
  Depression and Anxiety, 2013
• Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents
  Archives of Pediatrics & Adolescent Medicine, 2008
• Effects of Xanomeline, a Selective Muscarinic Receptor Agonist, on Cognitive Function and Behavioral Symptoms in Alzheimer Disease
  Archives of Neurology, 1997